JP2021525517A5 - - Google Patents
Info
- Publication number
- JP2021525517A5 JP2021525517A5 JP2020566612A JP2020566612A JP2021525517A5 JP 2021525517 A5 JP2021525517 A5 JP 2021525517A5 JP 2020566612 A JP2020566612 A JP 2020566612A JP 2020566612 A JP2020566612 A JP 2020566612A JP 2021525517 A5 JP2021525517 A5 JP 2021525517A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- peptide
- poly
- dna molecule
- nucleotide sequence
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024034648A JP2024063211A (ja) | 2018-05-30 | 2024-03-07 | 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2018/064299 | 2018-05-30 | ||
| EP2018064299 | 2018-05-30 | ||
| PCT/EP2019/064109 WO2019229193A1 (en) | 2018-05-30 | 2019-05-29 | Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034648A Division JP2024063211A (ja) | 2018-05-30 | 2024-03-07 | 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525517A JP2021525517A (ja) | 2021-09-27 |
| JP2021525517A5 true JP2021525517A5 (https=) | 2022-05-31 |
| JPWO2019229193A5 JPWO2019229193A5 (https=) | 2022-05-31 |
Family
ID=62620827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566612A Pending JP2021525517A (ja) | 2018-05-30 | 2019-05-29 | 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング |
| JP2024034648A Pending JP2024063211A (ja) | 2018-05-30 | 2024-03-07 | 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034648A Pending JP2024063211A (ja) | 2018-05-30 | 2024-03-07 | 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210254106A1 (https=) |
| EP (1) | EP3802841A1 (https=) |
| JP (2) | JP2021525517A (https=) |
| KR (1) | KR20210016446A (https=) |
| CN (1) | CN112384627A (https=) |
| AU (1) | AU2019276261A1 (https=) |
| BR (1) | BR112020024354A2 (https=) |
| CA (1) | CA3100112A1 (https=) |
| EA (1) | EA202092807A1 (https=) |
| MX (1) | MX2020012895A (https=) |
| SG (1) | SG11202011280SA (https=) |
| WO (1) | WO2019229193A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114181901B (zh) * | 2021-12-08 | 2024-02-02 | 杭州中赢生物医疗科技有限公司 | 一种免疫细胞的体外诱导扩增和冻存的方法 |
| EP4522736A2 (en) * | 2022-05-10 | 2025-03-19 | Editas Medicine, Inc. | Genome editing of b cells |
| EP4698226A2 (en) * | 2023-04-17 | 2026-02-25 | Be Biopharma, Inc. | Engineered cell preparations for treatment of hemophilia |
| CN117063890B (zh) * | 2023-07-11 | 2025-12-05 | 吉林大学 | 一种heca基因不表达的异种移植供体猪及制备方法 |
| WO2025147573A2 (en) * | 2024-01-05 | 2025-07-10 | Immusoft Corporation | Glp-1 expressing modified b cells for the treatment of metabolic disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| ATE271122T1 (de) | 1996-11-12 | 2004-07-15 | Pfizer | Attenuierter lebender neospora impfstoff |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| AU2002953381A0 (en) * | 2002-12-18 | 2003-01-09 | Diatech Pty Ltd | In vivo affinity maturation scheme |
| EP1646715B1 (en) | 2003-07-22 | 2010-05-12 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
| US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| WO2012063048A1 (en) * | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
| US20130102031A1 (en) * | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
| JP6262768B2 (ja) | 2013-01-03 | 2018-01-17 | セルトリオン， インク． | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
| AU2016243052C1 (en) * | 2015-04-03 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of B-cells |
| EP3313871A1 (en) | 2015-06-26 | 2018-05-02 | Institute for Research in Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| AU2016317936A1 (en) * | 2015-09-04 | 2018-03-08 | Tocagen Inc. | Recombinant vectors comprising 2A peptide |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
-
2019
- 2019-05-29 KR KR1020207038076A patent/KR20210016446A/ko not_active Withdrawn
- 2019-05-29 WO PCT/EP2019/064109 patent/WO2019229193A1/en not_active Ceased
- 2019-05-29 SG SG11202011280SA patent/SG11202011280SA/en unknown
- 2019-05-29 EP EP19730275.5A patent/EP3802841A1/en active Pending
- 2019-05-29 US US17/059,112 patent/US20210254106A1/en active Pending
- 2019-05-29 CN CN201980046344.7A patent/CN112384627A/zh active Pending
- 2019-05-29 MX MX2020012895A patent/MX2020012895A/es unknown
- 2019-05-29 EA EA202092807A patent/EA202092807A1/ru unknown
- 2019-05-29 AU AU2019276261A patent/AU2019276261A1/en not_active Abandoned
- 2019-05-29 CA CA3100112A patent/CA3100112A1/en active Pending
- 2019-05-29 BR BR112020024354-0A patent/BR112020024354A2/pt unknown
- 2019-05-29 JP JP2020566612A patent/JP2021525517A/ja active Pending
-
2024
- 2024-03-07 JP JP2024034648A patent/JP2024063211A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525517A5 (https=) | ||
| KR102503130B1 (ko) | 내인성 t 세포 수용체의 표적화된 대체 | |
| US11591381B2 (en) | Gene-edited natural killer cells | |
| AU2018226857B2 (en) | Compositions and methods for immunotherapy | |
| WO2017070429A1 (en) | Methods involving editing polynucleotides that encode t cell receptor | |
| JP2023552816A (ja) | 細胞内のｍｈｃクラスｉｉを低減する組成物及び方法 | |
| IL303970A (en) | Compositions and methods for genetically modifying ciita in a cell | |
| AU2019376903A1 (en) | Anti-LIV1 immune cell cancer therapy | |
| JP2023501617A (ja) | Ｃａｒ－ｔ細胞を製造する方法 | |
| US20230014010A1 (en) | Engineered cells with improved protection from natural killer cell killing | |
| KR20210092236A (ko) | 항-ptk7 면역세포 암 치료법 | |
| KR20180018457A (ko) | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 | |
| Hudecek et al. | Minicircle-based engineering of chimeric antigen receptor (CAR) T cells | |
| WO2021095013A1 (en) | Manufacturing process for making t cells expressing chimeric antigen receptors | |
| Arroyo-Olarte et al. | Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer: R. Arroyo-Olarte et al. | |
| JP2025525437A (ja) | 操作されたｔ細胞 | |
| US20250034558A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| EP4526333A2 (en) | Compositions and methods for engineering cells | |
| JPWO2019229193A5 (https=) | ||
| US20260071238A1 (en) | Materials and processes for engineering hypoimmunogenicity | |
| US20250197811A1 (en) | Compositions and methods for generating cells with reduced immunogenicity | |
| WO2023233342A2 (en) | Gene-edited natural killer cells | |
| US20260071189A1 (en) | Biomaterials and processes for immune synapse modulation of hypoimmunogenicity | |
| WO2024233505A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| AU2024233625A1 (en) | Systems targeting psma and ca9 |